Intestinal handling of dietary proteins usually prevents local inflammatory and immune responses and promotes oral tolerance. However， in ~?1% of the world population， gluten proteins from wheat and related cereals trigger an HLA DQ2/8-restricted T1 immune and antibody response leading to celiac disease. Prior epithelial stress and innate immune activation are essential for breaking oral tolerance to the gluten component gliadin. How gliadin subverts host intestinal mucosal defenses remains elusive. Here， we show that the α-gliadin-derived LGQQQPFPPQQPY peptide (P31-43) inhibits the function of cystic?fibrosis transmembrane conductance regulator (CFTR)， an anion channel pivotal for epithelial adaptatio... More
Intestinal handling of dietary proteins usually prevents local inflammatory and immune responses and promotes oral tolerance. However， in ~?1% of the world population， gluten proteins from wheat and related cereals trigger an HLA DQ2/8-restricted T1 immune and antibody response leading to celiac disease. Prior epithelial stress and innate immune activation are essential for breaking oral tolerance to the gluten component gliadin. How gliadin subverts host intestinal mucosal defenses remains elusive. Here， we show that the α-gliadin-derived LGQQQPFPPQQPY peptide (P31-43) inhibits the function of cystic?fibrosis transmembrane conductance regulator (CFTR)， an anion channel pivotal for epithelial adaptation to cell-autonomous or environmental stress. P31-43 binds to， and reduces ATPase activity of， the nucleotide-binding domain-1 (NBD1) of CFTR， thus impairing CFTR function. This generates epithelial stress， tissue transglutaminase and inflammasome activation， NF-κB nuclear translocation and IL-15 production， that all can be prevented by potentiators of CFTR channel gating. The CFTR potentiator VX-770 attenuates gliadin-induced inflammation and promotes a tolerogenic response in gluten-sensitive mice and cells from celiac patients. Our results unveil a primordial role for CFTR as a central hub orchestrating gliadin activities and identify a novel therapeutic option for celiac disease.
